Basal Cell Carcinoma (BCC)
BCC is the most common form of skin cancer and the most common type of all cancers, typically developing on sun-exposed areas of the skin.
Mucus-Driven Diseases
Mucus-driven diseases, including some chronic lung conditions, are characterized by thick, excessive mucus that can make breathing difficult and raise the risk of infections.
FLD-103 for Basal Cell Carcinoma
FLD-103 is a non-surgical therapy designed to target basal cell carcinoma through local injection directly into the tumor. Currently being investigated in a Phase 1/2a clinical trial, FLD-103 is developed to minimize scarring and reduce the impact of repeated surgeries.
FLD-201 for Mucus-Driven Diseases
FLD-201 is an inhalation therapy for mucus-driven lung diseases, designed to address the underlying mechanism of excess mucus build-up and help improve breathing and quality of life for patients living with chronic lung conditions. FLD-201 is currently in the preclinical development phase.
Discovery & Preclinical Research
Scientists start by identifying a promising molecule.
Lab tests and preclinical studies help understand how it works and if it's safe to move forward.
Clinical Trial: Phase 1
To assess safety & dosage
Small group of healthy volunteers or patients
Clinical Trial: Phase 2
To evaluate effectiveness & confirm safety
Larger group of patients
Clinical Trial: Phase 3
To confirm effectiveness & monitor safety
Even larger group of patients
Review & Approval
Throughout all phases, regulatory agencies such as the FDA and Health Canada review study data to ensure that human trials are safe for the patients.
At the end of Phase 3, they decide whether to approve the drug or treatment for public use.
Ongoing Monitoring
Even after approval, regulatory agencies continue to monitor safety and effectiveness.
Patient safety always comes first.